A Case Study of Gestational Gigantomastia
Background G estational gigantomastia is a rare condition characterized by rapid breast growth during pregnancy. The increased breast size leads to pain, ulceration, infection, bleeding, necrosis, and difficulty with mobility and can be fatal. Management is challenging and requires pain control, extensive wound care, psychological counseling, and surgical intervention. This case of bilateral gestational gigantomastia resulted in pregnancy termination.
Case
A 33-year-old woman presented to the quaternary academic medical center with gigantomastia at 15 weeks gestation. On presentation, her breasts were erythematous, firm, and tender. Laboratory findings included hypercalcemia; decreased intact parathyroid hormone levels; and elevated white blood cells, lactate levels, and parathyroid hormone-related protein. She reported severe constipation, anorexia, visual changes, headache, and fatigue. Diagnostic studies included abdominal and thyroid ultrasounds, chest computed tomography, and biopsy of chest wall tissue mass. Nephrolithiasis, breast hyperplasia, and axillary lymphadenopathy were confirmed. Treatment was initiated with intravenous fluids and calcitonin. The breast mass continued to grow, and she developed venous stasis ulcers that required frequent wound care. She agreed to pregnancy termination because of worsening gigantomastia and potentially poor surgical outcomes related to increased risk of hemorrhage.
Conclusion
Interdisciplinary collaboration was imperative for provision of holistic care and successful patient outcomes. Nurse accountability for patient education and emotional support continued throughout an extensive hospitalization. Nurses supported the woman through the difficult decision to terminate her pregnancy, provided anticipatory guidance regarding probable mastectomies, and offered coping strategies for separation anxiety.
A Triad of Autoimmune Disorders and Obstetric Hemorrhage
Background S tatistics show that rates of maternal morbidity have been increasing since 1998, and decreasing this trend is leading initiative in the United States. In 2010, the California Maternal Quality Care Collaborative Obstetric Hemorrhage Task Force released a toolkit to improve interprofessional readiness, recognition, and response to obstetric hemorrhage in an effort to decrease maternal morbidity. Our institution participated in the collaborative and developed a standardized response to obstetric hemorrhage, which is critical for management in unusual and high-risk situations.
Case
A 22-year-old gravida 1, para woman with rheumatoid arthritis, systemic lupus erythematosus, and idiopathic thrombocytopenic purpura presented for care. The interprofessional team caring for this woman felt it optimal to induce labor at 40 weeks gestation to mitigate bleeding complications and allow for pain management via regional anesthesia. After 24 hours of labor, a decision was made to perform a primary cesarean. During surgery, placenta percreta was diagnosed. A massive transfusion protocol, cell saver technology, and pharmacologic management were implemented and hysterectomy was performed. The woman and her newborn were discharged to home in good condition 4 days after birth.
Conclusion
This woman's triad of autoimmune disorders was unusual and significant. The team implemented an evidence-based, planned, interprofessional approach that involved safety briefings and team communication during the provision of care. This approach decreases maternal morbidity and improves patient outcomes. The nurse's recognition of and response to obstetric hemorrhage is critical for safe life-saving care.
